Global biotechnology company Alvotech SA (NASDAQ:ALVO) and UK pharmaceutical company Advanz Pharma announced on Monday that the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application for AVT23, a proposed biosimilar to Xolair (omalizumab).
AVT23 was developed by Alvotech in collaboration with Kashiv BioSciences LLC, with Advanz Pharma holding commercial rights in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted a separate Marketing Authorisation Application for AVT23 earlier this year.
Omalizumab is a prescription biologic used to manage severe persistent allergic asthma, chronic spontaneous urticaria, and severe chronic rhinosinusitis with nasal polyps.
AVT23 is designed as a humanised monoclonal antibody targeting free immunoglobulin E (IgE), providing a biosimilar alternative to Xolair. The EMA acceptance represents a key regulatory milestone for the commercialisation of AVT23 in Europe.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe